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This study evaluates various techniques for producing mesalamine (5ASA)-loaded particles employing 
chitosan as a biopolymer: (1) the polyelectrolyte complexation of chitosan with phthalate hypromelose 
(HP), (2) the chemical crosslinking of chitosan with genipin and (3) the water-in-oil emulsion method 
associated with chemical crosslinking with genipin. Systems were characterized by dynamic light 
scattering, zeta potential (ζ), powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy 
(FTIR) and a drug release profile. Method (1) was efficiently produced unloaded nanoparticles (491 nm, 
PdI=0.26 and ζ = 23.2), but the conditions for chitosan and HP cross-linking enhanced the precipitation of 
5ASA. Method (2) caused the degradation of the drug. Method 3 produced sub-micron and microparticles, 
thereby varying the agitation method; 3 h magnetic agitation resulted in 2692 nm, Pdi = 0.6 and ζ = 46, 
while Ultra-Turrax, 5 min produced submicron particles (537 nm, PdI = 0.6). The percentage yield was 
approximately 50%, which is very satisfactory considering the impossibility of encapsulating 5ASA 
using other methods. FTIR showed the covalent interaction of chitosan and genipin.  The drug release 
was rapid in acidic fluid, but in neutral pH a slower release was obtained in the initial stage, followed 
by rapid release, which may ensure the controlled release of 5ASA in the colon.
Keywords: Emulsion method. Polyelectrolyte crosslinking. Chemical cross-linking. Chitosan. 
Mesalazine.
INTRODUCTION
Inflammatory bowel disease (IBD) is a generalized 
term for a group of chronic diseases affecting the 
gastrointestinal system, including ulcerative colitis (UC) 
and Crohn’s disease (CD) (Hua et al., 2015). Mesalamine, 
also called 5-aminosalicylic acid (5ASA), has been used to 
treat IBD for more than 70 years with proven efficacy. It is 
estimated that the total market value will reach $ 6.2 billion 
in 2017, which emphasizes the importance of research in 
this sector (Talaei et al., 2013). The general principle of 
pharmacotherapy in IBD is to induce remission events 
and prevent new episodes during remission (Pertuit et al., 
2007). The treatment of UC and CD depends on factors 
such as the severity and subtype of the disease, as 
well as pre-existing diseases and patient tolerance to 
pharmacotherapy (Lautenschläger et al., 2014). The most 
common classes of drugs are anti-inflammatory agents 
such as 5ASA, which are used mainly in mild to moderate 
conditions, and corticosteroid and immunosuppressive 
agents, which are more effective in the treatment of more 
severe forms of IBD (Talaei et al., 2013).
The efficacy of many drugs is usually limited by low 
solubility, low stability, and a need for increasing potency, 
and in many cases, only a low fraction of the administered 
dose actually reaches the site of action; most of the drug 
diffuses through the body (Moura, Martins, Duarte, 
2015a). The main obstacle faced by treatment with 5ASA 
in conventional dosage forms is to achieve local levels 
of the drug in the inflamed mucosa without the use of 
dosage forms that are less acceptable to patients, such as 
enemas. The low bioavailability of drugs and low patience 
compliance may result in hospitalizations and failure of 
the treatment (Viscido et al., 2014).
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When administered orally, 5-ASA is rapidly and 
completely absorbed by the upper portion of the intestine 
and only reaches and remains in the colon at low levels. 
Therefore, it is of extreme importance to promote the local 
release of the drug for greater therapeutic success with 
fewer adverse effects and less drug loss (Pertuit et al., 
2007). Thus, gastroresistant drug delivery systems may 
delay the early release of the drug and allow enteric or 
colonic release. In addition to the early absorption of 
drugs, colonic drug delivery is affected by the mucous 
barrier: a thick and abundant layer of mucus is present in 
this pathway, which may prevent penetration of the drug 
delivery system or depuration by peristaltic movements 
and food bolus (Date, Hanes, Ensign, 2016).
Micro and nanoparticles can be designed to reach 
the colon using gastroresistant polymers. Due to the 
reduced size of the micro and nanoparticles, they can 
reach the firmly adhered mucus layer via passive diffusion 
without being eliminated with the peristaltic movements. 
In addition, submicronic particles (<300 nm) may favor 
capture by immune cells, which are highly proliferated 
in the inflamed colonic mucosa; this strategy targets the 
release of drug at the site of action (Lamprecht, Schäfer, 
Lehr, 2001; Moulari et al., 2008). 
The use of hydrophilic polymers, especially polymers 
with a positive charge such as chitosan, may favor the 
penetration of micro- and hydrophilic micro- and nano-
particles and their interaction with mucus glycoproteins, 
which are negatively charged, thereby increasing their 
retention in a phenomenon known as mucoadhesion 
(Carvalho et al., 2012; Ensign, Cone, Hanes, 2012). In 
this manner, micro and nanoparticles can be promising 
colonic drug delivery systems due to the controlled release 
of drugs in the TGI, targeting capacity, mucoadhesion 
and consequent increase in bioavailability. All of these 
properties may allow the reduction of administered doses, 
as well as reduction of toxicity and adverse effects.
Another strategy to prolong release in TGI is the 
polysaccharide-based nanoparticles obtained by covalent 
cross-linking of chitosan with crosslinking agents such as 
glutaraldehyde or genipin, which can delay the premature 
disintegration in TGI (Kumar, Su,Velusamy, 2016; 
Muzzarelli et al., 2016).
Based on the potential of chitosan in the development 
of mucoadhesive systems and the need of development of 
new drug delivery systems that target the colon, especially 
for IBD treatment, this work aims to develop chitosan 
micro and nanoparticles for 5-ASA incorporation. Some 
attempts to produce chitosan nanoparticles of 5ASA are 
found in the literature, such as the studies of Mura et al. 
(2012), Mladenovska et al. (2007) and Aguzzi et al. 
(2011), which employed gastroresistant polymers in 
combination with spray dry techniques (Aguzzi et al., 
2011; Mladenovska et al., 2007; Mura et al., 2012). 
In this study, our goal is to evaluate and compare 
different low cost techniques for producing 5ASA-loaded 
submicronic particles, taking into consideration the limited 
solubility of the drug in both organic and aqueous solvents, 
which limits many physical processes that requires 
solubilization of the drug prior to particle production. 
The novelty is the comparison of three approaches 
employing chitosan as a biopolymer to produce 5ASA 
particles that have not been tested before: polyelectrolyte 
complexation of chitosan with phthalate hypromelose 
(PH), chemical crosslinking of chitosan with genipin 
and water in oil emulsion (W/O) method associated 
with chemical crosslinking with genipin. Systems were 
physico-chemically characterized and the drug release 
profile varying the pH was performed as proof of concept. 
Since 5ASA is greatly limited pH-dependent solubility and 
oxidation, this study was very important to discuss better 
approaches to handling 5ASA during encapsulation. 
MATERIAL AND METHODS
Material 
Mesalamine (5ASA), low viscosity chitosan and 
HPLC-grade methanol were purchased from Sigma-
Aldrich, St. Louis, USA. The phthalate hypromellose 
(PH) was from HP-55 Shin-Etsu Chemical, Tokyo, Japan. 
Polysorbate 80 (Tween 80) and sodium hydroxide were 
from Vetec, Duque de Caxias, Brazil. Choridric acid and 
glacial acetic acid were from Proquimios, Rio de Janeiro, 
Brazil. 
Experimental
Method of polyelectrolyte complexation of chitosan
Nanoparticles were produced by low-viscosity 
chitosan dispersion at 0.1% w/v in 1% acetic acid, pH=5.5 
and hypromellose phthalate (HP) as ionic cross-linker at 
0.5% w/v in NaOH 1 M (pH=5.5), and 5ASA at 5 mg/mL 
in HCl 1 M pH=5.5 was incorporated into the chitosan 
dispersion to have the drug at 5% w/w to the polymeric 
weigh. The HP dispersion (2.0 mL) was dropwise added 
to 1.2 mL of chitosan dispersion under magnetic stirring, 
resulting in 3:1 chitosan/HP opalescent suspension. 
Samples using this method were named Poly Electrolyte 
Complexes (PECs) (Barbi et al., 2014). All procedures 
were performed in a dark room, and the samples were 
protected against light.
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Method of chemical crosslinking of chitosan with 
genipin
The method was adapted from Fonseca (2015). 
Chitosan was dispersed at 0.5% (w/v) in chloridric acid 
1 M; then 0.1% w/v polysorbate 80 and 5 mg/ml of 5ASA 
were added. Separately, 1 mM of genipin was dissolved 
in 10 mL of ethanol, and this solution was dropwise added 
into 10 mL of chitosan dispersion using a syringe immersed 
into the dispersion, pressing the plunger at 1 mL/min 
(Fonsêca, 2015). Two types of stirring were tested for the 
crosslinking reaction: magnetic stirring at 800 rpm for 3 h 
and high-performance dispersing instrument (T 25 digital 
Ultra Turrax, Ika) at 3,000 rpm for 5 min. The resulting 
dispersions were centrifuged at 3500 rpm and suspended 
in water for characterization. Samples using this method 
were named as Magnetic Stirred Chemical Cross-Linked 
Particles (Chem_Mag) and Ultra-Turrax Stirred Chemical 
Cross-Linked Particles (Chem_UT). All procedures were 
performed in a dark room, and the samples were protected 
against light.
Method of W/O emulsion followed by crosslinking of 
chitosan with genipin
The preparation procedure is similar to those 
reported by Moura et al. (2015) with minor modifications. 
Chitosan was dissolved at 0.5% p/v in aqueous HCl 
solution 0.1 M, and the resulting solution is the water-
dispersed phase, in which 5ASA was dissolved at 
5 mg/ml. A volume of 3 mL of this solution was then 
dispersed dropwise into a 40-mL mixture of mineral oil 
and Span 60 (2%, w/v), which was the organic phase, 
resulting in a water-to-oil phase ratio of 1/13.3 (v/v). 
The W/O emulsion formed, followed by homogenization 
with continuous stirring using a magnetic stirrer (Moura, 
Martins, Duarte, 2015).
Once the emulsion formed, a volume of 0.5 mL of 
genipin 70% (v/v) alcoholic solution was added dropwise 
to the W/O emulsion to obtain a solution with a ratio of 
genipin to chitosan of 1/6 (v/v). To cross-link particles, two 
stirring processes were tested: one using a magnetic stirrer 
at 800 rpm for 3 h, and a second using a high-performance 
dispersing instrument (T 25 digital Ultra Turrax, Ika) at 
3,000 rpm for 5 min, both at room temperature (25 °C).
The resulting particles were separated from the 
continuous phase by decanting and submitted to washing 
with hexane and decanted three times. the particles were 
dried at room temperature. Samples using this method 
were named Magnetic Stirred Emulsified Cross-Linked 
Particles (Emul_Mag) and Ultra-Turrax Stirred Chemical 
Cross-Linked Particles (Emul-UT). The complete 
procedure is schematically presented in Figure 1. All 
procedures were performed in a dark room, and the 
samples were protected against light.
Physicochemical characterization 
The samples were characterized by dynamic 
light scattering (DLS), polydispersity index (PdI) and 
electrophoretic mobility using a Zetasizer Nanoseries 
(Malvern Instruments, Ltd., Malvern, UK). The refraction 
indexes used were 1.33 and 1.55 for water and chitosan, 
respectively. All measurements were performed at 25 °C 
in triplicate. For each sample, the mean particle diameter, 
polydispersity and standard deviation of 10 determinations 
were calculated, applying multimodal analysis.
The shape of particles was examined via optical 
microscope coupled to a camera, and images were 
acquired using a scanning procedure. The microscope 
slide was divided into three sections in the longitudinal 
direction. An average of 50 images per slide were acquired 
following a sequence from left to right (Moura, Martins, 
Duarte, 2015).
Fourier Transform Infrared Spectroscopy (FTIR) 
Particles used in the analysis were previously 
lyophilized to produce fine powder. Then, the powder 
was mixed with KBr and pressed into a pellet. The FTIR 
spectra were recorded using a FTIR (Fourier transform 
FIGURE 1 - Organogram of method of production of submicron 
particles named as Magnetic Stirred Emulsified Cross-Linked 
Particles (Emul_Mag) and Ultra-Turrax Stirred Chemical Cross-
Linked Particles (Emul-UT).
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infrared spectrometer, Vertex 70, Bruker, Germany) 
operating at room temperature, in the frequency range 
4000 e 400 cm-1 and 4 cm-1 resolution. FTIR spectra of 
pure polymers and drug were also recorded for differential 
comparison.
Powder X-ray Diffraction analysis (PXRD)
PXRD data were recorded at room temperature 
(293 K) using an Ultima IV diffractometer (Rigaku, 
Tokyo, Japan) with θ−2θ geometry. Cu Kα radiation 
(λ = 1.5418 Å) was generated using a sealed tube at 
40 kV and 30 mA. The data were collected with a step 
size of 0.02° in 2θ. The speed of scanning was 1° 2θ/min, 
from 3° to 50° in 2θ. The samples were finely ground and 
mounted onto a grooved glass slide employed as a sample 
holder. The experimental PXRD patterns were compared 
with those calculated by importing the crystal structures 
determined for the 5ASA free base, 5ASA hydrochloride 
and 5ASA hydrochloride monohydrate (CCDC code: 
SAQJAV02; SAQJEZ; PUVMAU) (Banić-Tomišić, 
Kojić-Prodić, Širola, 1997; Cherukuvada et al., 2013) 
forms into Mercury (Macrae et al., 2008).
Analytical characterization
A high-performance liquid chromatography (HPLC) 
analytical methodology, developed and validated, was 
used to measure drug concentration. Briefly, a Shimadzu 
HPLC system was used for the analyses, consisting 
of a CBM-20A Solvent Delivery Module, SPD-20A 
Spectrophotometric Detector (set at 254 nm) and a 
SIL-20AHT automatic injection module. A reverse-phase 
C18 column (Acqua, Phenomenex) of 150 mm, 4.6 mm 
I.D. and 5-µm particle size was used. The isocratic 
mobile phase was a mixture of methanol/phosphate buffer 
0.05 M, pH 6.6, at 9:1 (v/v), flowing at 0.6 mL/min. It 
was constructed calibration curve of standard solutions 
of 5ASA ranged from 1 µg/mL to 50 µg/mL dissolved 
in mobile phase, and the regression line obtained was 
y = 27324x – 1212.5, with r2=0.999, precision of 2.5, 
10 and 50 µg/mL among 0.1-0.5% and accuracy in the 
range of 97.8-98.5%. LD and LQ of 0.0102 µg/mL and 
0.034 µg/mL, respectively, and precision and accuracy in 
the acceptable range of ICH guidelines.
Percentage yield
An accurate weight of chitosan particles was 
dispersed in 15 mL of NaOH 1 M for chitosan precipitation 
and 5ASA solubilization. The system was centrifuged at 
3600 rpm for 30 min, and the supernatant was diluted in 
mobile phase, filtered through 45 µm membrane for HPLC 
injection. 
Percentage yield was calculated from the weight of 
placebo, and 5ASA-encapsulated particles recovered from 
each batch in relation to the starting material were used 
in the preparation of chitosan particles. The percentage 
yield of prepared microspheres was determined using the 
formula as follows:
Percentage yield = Practical yield/Theoretical yield ×100
In vitro drug release
The dissolution apparatus (299 Nova Ética, Brazil) 
was set up as follows: dissolution compartment volume 
300 mL, stirred at 50 rpm. Synthetic cellulose acetate 
membrane with molar mass cut-off 12–14 kDa (Spectrum) 
previously treated with Milli-Q water at 100 °C for 15 
min. The membrane was cut into 6-cm cylinders filled 
with 2 mL of samples, and both sides of the bag were tied 
with a twine knot. 
The experiment was performed for gastric 
dissolution of medium composed of chloridric acid buffer 
0,1 M, pH=1.3 for 1 h, followed by enteric dissolution 
medium composed of monobasic phosphate buffer 0.05 M, 
pH=6.6, during 6 h. All experiments were performed at 
37°C, and sink conditions were maintained. Samples 
of 1 mL were withdrawn from the receptor fluid and the 
volume withdrawn was replaced with fresh receptor fluid. 
Each formulation was analyzed in triplicate, with 5ASA at 
4 mg/mL. 5ASA was quantitatively determined by HPLC 
with the UV–Vis detector at 254 nm.
The drug release kinetics were evaluated by different 
mathematical models, such as zero order, first order, 
Weibull, Korsmeyer-Peppas and Higuchi. To select the 
best model that fit the release profile obtained for the 
samples, the determination coefficient (R2) was used 
(Costa, Sousa Lobo, 2001; Fredenberg et al., 2011).
RESULTS AND DISCUSSION
Method of polyelectrolyte complexation of 
chitosan
Unloaded nanoparticles were successfully produced 
using this method, resulting in a homogenous opalescent 
dispersion containing nanoparticles with a mean diameter 
of 491 nm, PdI 0.26 and zeta potential of + 23.2 mV 
(Table I). The incorporation of the drug into a chitosan 
solution during condensation was chosen due to the 
better stability in acidic than basic solution. Previous 
incorporation of 5ASA into HP solution resulted in 
a brown dispersion due to oxidation. However, even 
careful handling of 5ASA-loaded nanoparticles resulted 
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in a turbid dispersion with brown suspended particles, 
different from the unloaded nanoparticles, suggesting 
precipitation of the drug. Loaded samples were centrifuged 
for encapsulation efficiency determination and 5ASA 
was not detected in the supernatant. This could suggest 
total entrapment of the drug into nanoparticles, or the 
drug could not be detected because it had precipitated. 
Previous to polyelectrolyte complexation, the chitosan 
dispersion containing the drug was totally clear. The brown 
particles were observed after complexation. The 5ASA 
can exist in different ionic forms depending on the pH of 
the solution. Below pKa=2.2, 5ASA is cationic; between 
pKa 2.02 and 5.8, it is zwitterionic; and above pKa 12, it is 
anionic (Zerrouk et al., 1998). The pH of the nanoparticle 
suspensions is 5.5; the zwitterionic form predominates and 
may be less soluble than the ionic forms. These findings 
indicate that polyelectrolyte complexation is a method 
not recommended for 5ASA nano-encapsulation, since it 
depends on the drugs’ solubility for complexation, and the 
conditions for chitosan and HP cross-linking enhance the 
precipitation of the 5ASA.
Method of chemical crosslinking of chitosan with 
genipin
Chemical crosslinking of chitosan with genipin 
resulted in a dark opalescent dispersion of 5ASA-loaded 
samples. The resulted dispersions produced using both 
stirring methods, magnetic and Ultra-Turrax, presented 
the same aspect. The opalescence may indicate colloidal 
or nanoparticle formation (see size and zeta potential in 
Table I), but the color is problematic. One mechanism 
by which 5ASA could degrade appears to depend on the 
production of colored black imines (Zerrouk et al., 1998). 
The oxidation of 5ASA is also light-sensitive, but all 
experiments were performed in a dark room or under UV 
light. Therefore, the conditions found for this crosslinking 
method enhanced degradation of the drug and are not 
recommended for 5ASA encapsulation.
Method of W/O emulsion followed by 
crosslinking of chitosan with genipin
In this method, the variable parameter was the 
stirring process: either magnetic/long time and Ultra-
Turrax/short time. The size distribution and zeta potential 
results are in Table I. The method resulted in sub-micron 
particles, which act as a mucous penetration system. The 
high zeta potential is desirable for colloidal stability.
The incorporation of the drug was tested for Emul-
samples, since they resulted in stable particles. The 
percentage yield was calculated based on the total particle 
weight, and the quantification of the drug into the particles 
followed their destruction. It was not possible to calculate 
the encapsulation efficiency, because it would be necessary 
to quantify the unloaded drug into the supernatant, and in 
case of emulsion method, the oily supernatant was washed, 
precluding the quantification of 5ASA. Percentage yield 
results are shown in Table I. It was found that ultra-turrax 
stirring was slightly more effective in loading 5ASA, 
suggesting that the intensity of agitation is more important 
than time of agitation, since ultra-turrax was more rapid 
(5 min) than magnetic stirring (3 h). The values found near 
50% are very satisfactory, considering the impossibility 
of encapsulating 5ASA using polyelectrolyte, as well 
as chemical cross-linking. Notably, the incorporation 
of 5ASA is limited to its solubility in HCl, which was 
experimentally found as 5 mg/mL. Since we solubilized 
5ASA at 5 mg/mL in the internal aqueous phase of 
emulsion, the maximum amount of 5ASA possible to 
incorporate in the system was used in this method.
The microscopic images of particles are shown in 
Figure 2. The figure shows that 5ASA-loaded and unloaded 
particles are nearly spherical and blue. Moura et al. (2015) 
attributed this color to the formation of cross-linked 
particles oxygen-radical-induced polymerization of 
genipin and its subsequent reaction with chitosan amino 
groups. DLS showed the high polydispersity of the 
systems, which correlates with the microscopy image. 
TABLE I - Size, zeta potential and percentage yield of 5ASA-loaded particles produced by different methods of cross-link
Size (nm) PdI Zeta potential (mV) Percentage yield (% w/v)
PEC 532 nm ± 45 0.29 ± 0.2 25.7 ± 2.3 *
Unloaded PEC 491 nm ± 83 0.26 ± 0.1 23.2 ± 1.2 *
Chem-Mag 724± 209 0.36 ± 0.3 724± 209 *
Chem-UT 854 ± 121 0.63 ± 0.1 59.0 ± 2.5 *
Emul-Mag 2692 ± 717 0.58 ± 0.1 46.0 ± 5.4 47.21 ± 0.08
Emul-UT 537 ± 169 0.57 ± 0.1 43.3 ± 1.5 58.40 ± 4.62
*not determined
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Since a simple optical microscope was used, it was not 
possible to obtain images of smaller particles, which could 
be visualized by scanning electron microscopy (SEM). 
Although the image does not represent DLS behavior, it is 
presented to show the gel-like structure and the amorphous 
morphology of the particles. 
Powder X-ray Diffraction (PXRD)
Powder X-ray Diffraction (PXRD) analyzes were 
performed to characterize the initial polycrystalline 
material and submicron particles. Figure 3 shows the 
experimental diffractograms of the unloaded Emul-Mag 
and Emul-UT. The samples are observed to be crystalline 
materials, because they show diffraction peaks at different 
angles. Comparison of the two samples shows that the 
Bragg peaks appear at coincident angles, indicating that 
the stirring processes (magnetic and Ultra-Turrax) did not 
generate different crystalline materials. 
The experimental diffractograms of 5ASA loaded 
samples were compared with the experimental unloaded 
Emul-Mag and Emul-UT, and the calculated diffractogram 
from the CCDC CODE: SAQJAV02 was found in the 
database of crystalline organic structures (CCDC-CSD) 
for the free base of 5ASA (Cherukuvada et al., 2013). 
These diffractograms are in Figure 4 and show that the 
Bragg peaks generated for the unloaded and loaded 
samples are coincident. In those samples, it was not 
possible to identify coincident angles of Bragg peaks 
related to the free base of 5ASA. These results indicate 
that 5ASA may have been fully incorporated into the 
system, or it was not possible to identify the drug phase 
in the sample, due to the low proportion in the systems 
(lower or equal to 5% w/w). A similar result was found 
in Nunes, Mahendrasingam and Suryanarayanan (2005) 
and in Varasteh et al. (2009). Another possibility is that 
drug is dispersed in the amorphous state, and thus, there 
are no drug peaks in the particles. Moreover, there was 
no difference between the two types of agitation for the 
crystalline materials obtained.
The  expe r imen ta l  d i f f r ac tog rams  o f  t he 
5ASA-loaded Emul-Mag and Emul-UT were compared 
to the calculated diffractograms of 5ASA free base, 5ASA 
hydrochloride and 5ASA hydrochloride monohydrate 
(CCDC CODE: SAQJAV02; SAQJEZ; PUVMAU), 
respectively (Banić-Tomišić, Kojić-Prodić, Širola, 1997; 
Cherukuvada et al., 2013; Dobson, Gerkin, 1998). This 
comparison was performed to evaluate whether there is a 
crystalline phase transition of the incorporated drug. As 
observed in Figure 5, there was no identification of Bragg 
peaks for submicron particles at the correspondent angles 
of crystalline forms of 5ASA, demonstrating no phase 
transition, and thus, the obtained material can be a new 
crystalline form or a phase mixture. 
FIGURE 2 - Optical microscope image of chitosan particles produced w/o emulsion followed by crosslinking of chitosan with 
genipin. Left: cross-linking under magnetic stirring for 3 h. Right: cross-linking under ultra turrax for 5 min. Images treated using 
AxioVision software.
FIGURE 3 - Experimental diffractograms generated for unloaded 
Emul-Mag and Emul-UT.
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FTIR
FTIR analyses show the bands and characteristic 
stretches of chitosan (Brugnerotto et al. ,  2001). 
The literature proposes two distinct mechanisms 
for crosslinking between chitosan and genipin. One 
mechanism (mechanism A) is based on a slower reaction 
for nucleophilic substitution, which involves a nucleophilic 
attack on the carbon of the ester group of the genipin; 
substitution of this group is achieved with a secondary 
amide with the release of methanol (Figure 6). The second 
proposal (mechanism B) is related to the reaction in 
FIGURE 4 - Experimental diffractograms of unloaded and 
5ASA-loaded Emul-Mag (a) end Emul-UT (b) and 5ASA free 
base (CCDC CODE: SAQJAV02) (in a and b).
FIGURE 5 - Experimental diffractograms of 5ASA-loaded Emul-
Mag and Emul-UT compared to experimental and calculated 
diffractograms of 5ASA free base, 5ASA hydrochloride and 
5ASA hydrochloride monohydrate (CCDC CODE: SAQJAV02; 
SAQJEZ; PUVMAU).
FIGURE 6 - Proposed mechanisms for chitosan and genipin cross-linking. Source: (Butler, Yiu-Fai, Pudney, 2003).
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which a nucleophilic attack of the primary amine on the 
carbon “C3” of genipin forms an intermediate aldehyde. 
There is an opening of the heterocyclic ring of genipin, 
which is attacked by the secondary amine group to form 
a heterocyclic compound attached to the amine group, 
according to Figure 6 (Butler, Ng, Pudney, 2003). 
FTIR spectra were obtained for the pure chitosan 
and chitosan crosslinked with genipin are shown in 
Figure 7. The crosslinking probably occurred according to 
mechanism B, since there is no amide band (1650 cm-1) in 
the cross-linked material (Butler, Yiu-Fai, Pudney, 2003; 
Moura, Martins, Duarte, 2015). The C=O (1647 cm-1) 
and NH2 (1586 cm-1) bands presented in the spectrum of 
pure chitosan are no longer observed in the spectra of the 
crosslinked materials. The disappearance of these chitosan 
characteristic bands indicates that there was the attack of 
the amino group on the “C3” of genipin, generating the 
heterocyclic group with a tertiary amine. Moreover, there 
was a change in the chitosan fingerprint region for the 
particles, which corroborates the crosslinking process. 
Notably, the agitation procedures employed for particle 
production did not interfere in this characterization.
In Figure 8, the fingerprint region of the molecules 
is highlighted in red. There were no changes between 
the loaded and unloaded particles. According to 
Brugnerotto et al. (2001), the band near 2867 cm-1, 
highlighted in green, as well as the absence of bands near 
1560 cm-1, indicate the low acetylation of chitosan even in 
the presence of other materials (Brugnerotto et al., 2001).
The FTIR spectra in Figure 9 show the likely point 
of molecular interaction between 5ASA and chitosan. 
The attenuation of the band near 2852 cm-1 for 5ASA-
loaded samples is highlighted in red, and the inversion 
of intensity of the bands present near 2924 and 2932 cm-1 
is in blue. There was no difference between the agitation 
processes. To demonstrate the interaction on the C sp of 
chitosan, the relative intensity for the C-H bands from the 
highest-intensity band (near 3177 cm-1) was calculated and 
is shown in Table II.
The calculations demonstrated that the band near 
2852 cm-1 for the 5ASA-loaded Emul-UT sample was 
attenuated 39.59% relative to the unloaded sample. 
When comparing the relative intensities of the bands near 
2924 and 2932 cm -1 with those of unloaded particles, 
the attenuation was 31.78 and 26.10%, respectively. In 
addition to band attenuation, there was also an inversion of 
FIGURE 7 - FTIR spectra of chitosan, Emul-Mag e Emul-UT.
FIGURE 8 - FTIR spectra of unloaded and 5ASA-loaded Emul-
Mag and Emul-UT. Highlighted: fingerprint region (red) and 
band near 2867 cm -1 (green).
FIGURE 9 - FTIR Spectra of unloaded and 5ASA-loaded Emul-
Mag and Emul-UT, highlighting C-H bands in 2852 cm -1 (red) 
and band near 2924 and 2932 cm -1 (blue).
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intensity. The relative intensities were 83.33 and 81.30% 
for the bands at 2924 and 2932 cm -1, respectively, while 
the values for 5ASA-loaded Emul-UT were inverted: at 
2932 cm-1 the intensities were greater (55.20%) than for 
the band at 2932 cm -1 (51.55%).
The same was observed for 5ASA-loaded Emul-
Mag. The attenuation of the 2852 cm-1 band was 30.71% 
and the 2924 and 2932 cm -1 bands were 33.90 and 
23.94%, respectively. The inversion was also verified, 
since unloaded Emul-Mag showed relative intensities of 
78.30 and 76.15%, respectively, while for 5ASA-loaded 
samples, the inversion of relative intensities is verified. 
The relative intensity calculated for the band near 2924 
cm-1 was 44.40%, which is lower than that found for the 
band near 2932 cm-1 (52.21%). These results demonstrate 
that potential interactions between the drug and chitosan 
may occur at the C sp site of the chitosan molecule.
In vitro drug release 
In the drug release assay, it is important to ensure 
sink conditions, so that the concentration of the total 
components cannot achieve more than 10% in the release 
medium. This condition was assured consideration of 
the rate in the total weight of the components by the total 
volume of release medium, which in our case resulted in 
less than 1% w/v. 
The amount of 5ASA released was expressed as a 
percentage, which is plotted against time in Figure 10. It 
can be seen in Figure 10a that 5ASA was totally released 
from submicron particles in acidic medium. This result 
shows that covalent crosslinking cannot effectively 
promote gastro-resistance for the developed systems. For 
colonic delivery, the submicron particles produced here 
should be encapsulated into a gastro-resistance capsule, 
or a polymeric gastro-resistance coating may be tested.
The release profile obtained from colonic pH is 
shown in Figure 10b. There was fast release from free-
5ASA and Emul-UT samples, and the release profiles are 
overlapped. Emul-Mag was more effective in controlling 
drug release, since in the first 1 h there was 60% drug 
release, while more than 80% had already been released 
from Emul-UT and free-5ASA.
Structurally, FTIR and PXRD show no difference 
between Emul-UT and Emul-Mag. The retardation in 
the initial release of Emul-Mag can be attributed to the 
type and time of stirring process during the production of 
submicron particles. Thus, magnetic stirring may result in 
more stable covalent bonds between genipin and chitosan, 
due to the longer time for reaction and milder agitation, 
which retards 5ASA release.
The profiles obtained in the drug delivery assay 
were analyzed by mathematical models to identify the 
mechanisms involved in 5ASA release, and the R2 values 
are shown in Table III. The Weibull model showed the 
highest R2 and was used thus to discuss the data. This 
model expresses the accumulated fraction of the drug in 
solution at a given time, from which the shape parameter, 
b, characterizes the curve as exponential (b=1) (Case 1), 
sigmoid, S-shaped, with upward curvature followed by a 
turning point (b>1) (Case 2), or parabolic, with a higher 
initial slope and afterwards, which is consistent with the 
TABLE II - Calculation of relative intensities of bands approximately 2852.3 and 2932 cm -1 of unloaded and 5ASA-loaded Emul-
Mag and Emul-UT
Emul-UT 5ASA-Emul-UT
Intensity cm-1  Relative Intensity (%) Intensity cm
-1 Relative Intensity 
(%)
88.01 3177 100.00 74.95 3177 100.00
59.35 2852 67.44 20.87 2852 27.85
73.34 2924 83.33 38.64 2924 51.55
71.55 2932 81.30 41.37 2932 55.20
Emul-Mag 5ASA-Emul-Mag
Intensity cm-1 Relative Intensity (%) Intensity cm
-1 Relative Intensity 
(%)
56.35 3177 100.00 49.55 3177 100.00
33.97 2852 60.28 14.65 2852 29.57
44.12 2924 78.30 22.00 2924 44.40
42.91 2932 76.15 25.87 2932 52.21
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exponential (b<1) (Case 3) (Costa, Sousa Lobo, 2001). 
Table III shows the b values derived from the fitting 
of Weibull model to the entire drug release curve data. 
Values of b were significantly greater than 1, indicating 
the sigmoid profile.
A sigmoidal release profile characterized by slower 
release in the initial stage (0–1 h) followed by rapid release 
during the later stage (3–6 h) may ensure targeted drug 
release to the colon (Ali Asghar et al., 2009).
These results show controlled drug release in a 
neutral environment. Release in an acidic pH can be 
easily achieved by encapsulating the particles into gastro-
resistant capsules.
The initial aim of our study was to obtain <300 nm, 
but the methods employed resulted in >500 nm particles. 
Therefore, immune system targeting based on particle 
size was not accomplished, but this study did show the 
difficulty in stabilizing 5ASA using different methods 
to produce sub-micron particles. The emulsion method 
showed more efficacy because it allows protection of 
the drug in an acidic environment surrounded by an oily 
phase that avoids 5ASA oxidation. In addition, the drug 
release assay showed that Emul-samples have potential 
to control drug release in neutral pH. The polydispersity 
index was quite high, but the use of an appropriate scale-
up equipment, such as high-pressure homogenizer, may 
result in monodispersed and smaller particles. Therefore, 
this study importantly outlines a strategy to produce 
sub-micron particles of 5ASA for oral administration 
and colonic-controlled delivery, resulting in sub-micron 
particles that have great potential to traverse the loosely 
adhered mucus layer combined with a mucoadhesive 
polymer that can promote intimate contact with the 
inflamed mucosa, releasing 5ASA in a controlled manner. 
These results can be a starting point for formulators to 
delineate future experiments to study the nano- and micro-
encapsulation of 5ASA.
CONCLUSION
This study is important because it shows the 
limitations of encapsulating 5ASA in nano- and 
micro-particles using conventional techniques such as 
polyelectrolyte complexation of chitosan via polyanion 
and chemical crosslinking of chitosan with genipin. The 
successful method was the method that protected the drug 
against the reactional medium, namely, the W/O emulsion 
followed by crosslinking of chitosan with genipin. It was 
possible to solubilize the drug at an appropriately stable 
pH (acidic) and to protect the drug in the internal phase 
of the emulsion, while the chitosan and genipin reaction 
may occur in the surface of the droplet. The agitation 
process in this method was varied, including conditions 
combining magnetic/long time and Ultra-Turrax/short 
time treatments. There was no significant difference in 
the percent yield, but magnetic/long time agitation more 
efficiently prolonged drug release in neutral pH. Release in 
acidic pH can be easily handled by encapsulating particles 
into gastro-resistant capsules. These finds are very 
FIGURE 10 - Drug release profile of submicron particles Emul-Mag, Emul-UT and free-5ASA: (a) simulated gastric fluid; 
(b) simulated colonic fluid.
TABLE III - Determination coefficients (R2) obtained from drug 
release mathematical models fitting, and shape parameters (b) 




Zero order 0.2641 0.6487
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important for determining a suitable method to produce 
sub-micron particles for potential colonic release of 5ASA. 
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